Clinical Trials Logo
  1. Home
  2. Migraine With or Without Aura
  3. NCT02605174

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine — SPARTAN  

Migraine With or Without Aura Clinical Trial

Official title:
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)

Clinical Trial Summary

This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).

Clinical Trial Description

Participants will be asked to treat a migraine attack with study drug on an outpatient basis. Participants will be provided with a dosing card containing a dose for initial treatment and a second dose to be used for rescue or recurrence of migraine. Each participant's study participation will consist of screening (Visit 1) with a telephone contact within 7 days to confirm eligibility, a Treatment Period of up to 8 weeks, and End-of-Study (EoS) (Visit 2) within one week (7 days) of treating a single migraine attack. The total time on study is approximately up to 11 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02605174
Study type Interventional
Source Eli Lilly and Company
Contact
Status Completed
Phase Phase 3
Start date May 2016
Completion date June 30, 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT00792636 - A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period Phase 4
Completed NCT00383162 - A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) Phase 3
Completed NCT01986088 - Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study Phase 3
Completed NCT01978496 - Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine Phase 3
Completed NCT01989936 - Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan Phase 3
Completed NCT06245902 - An Acute Migraine Factorial Study Phase 2
Completed NCT03061734 - Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine Phase 2
Completed NCT00382993 - A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) Phase 3
Completed NCT01986270 - Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo Phase 3
Completed NCT03194555 - The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination Phase 2